BioPharm Asia is Providing Solutions to China’s Senior Citizens

NEW YORK & TONGHUA, China--(BUSINESS WIRE)-- Similar to many Western countries, China has an increasing proportion of its population entering the “senior citizens” ranks. These individuals have special medical needs and BioPharm Asia is taking steps to meet these challenges and to assist this growing segment to thrive in their “golden years”.

According to recent estimates, China has nearly 170 million of its population over 60 years of age, a level that exceeds the combined total population of the United Kingdom, France and Spain. It is estimated that this “senior” segment will grow substantially faster than China’s total population, thus representing a significant and expanding market with special needs, needs to which Chinese pharmaceutical industry must thoughtfully anticipate and respond. As a member of this industry, BioPharm Asia recognizes this obligation and is taking steps to develop new products to assist this special group.

BioPharm Asia is well suited to respond to these needs as it has operating units in herbal planting, manufacturing, distribution and pharmaceutical retail stores, the critical elements necessary to provide traditional Chinese and western medicines. An example of this is BioPharm Asia’s recent acquisition of the means to produce the proteins and amino acids used extensively for vitamins and various supplementary traditional Chinese medicines, as well as for food and cosmetics.

China’s 2010-2012 New Healthcare Reform has shown the government’s commitment to quality healthcare for all of its citizens. This commitment includes the investment of RMB 84 billion to expand medical insurance coverage and to improve the basic medical care available to China’s population. Funding such as this is one of the reasons that the health care market in China is expected to increase at an annual rate of 10% to 15%. Also in September this year, the Company signed a letter of intent to acquire Weifang Municipal Hospital. With BioPharm’s expertise in the design and implementation of health care systems, and its access to quality medicines, it believes this acquisition will result in a marked increase in the efficiency and effectiveness of the Weifang Municipal Hospital in servicing the medical needs of to its surrounding population, while selectively utilizing drugs manufactured by the Company.

As the senior segment of China’s population experiences significant growth in the coming years, we believe that BioPharm Asia will be an outstanding medical provider to its needs, with a resulting increased value to the Company’s shareholders.

About BioPharm Asia, Inc.

BioPharm Asia, Inc. is engaged in the retail sale of medical products in China, complemented by vertically integrated supporting functions that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. Following several successful acquisitions, the Company is completing the integration of its distribution channels and expanding its trading business (conducted through its retail stores as well as its distribution activities) to include pharmaceutical manufacturing and the cultivation and sale of medicinal raw materials. For more information, please visit http://www.biopharmasiainc.com.

Forward-looking statement: Except for certain historical information contained herein, the matters discussed in this news release contain forward-looking statements, including, but not limited to, statements relating to future expansion plans and growth in sales. These forward-looking statements involve a number of risks and uncertainties. Actual results may differ materially from those implied herein due to a number of factors, including, but not limited to, uncertainties in product demand, risks related to doing business in China, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors discussed in the company's most recent annual report and other filings with the U. S. Securities and Exchange Commission.

BioPharm Asia, Inc.Jianxiong Liu, 011-86-435-5211804
[email protected]

Source: BioPharm Asia, Inc.